60 Degrees Pharmaceuticals (NASDAQ: SXTP) updates legal opinion for ATM equity program

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.

The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/12/2026 - 04:36 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 12, 2026

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 12, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) filed an updated legal opinion of counsel regarding the shares of common stock issued and sold under its “at-the-market” equity offering program (the “ATM Program”) pursuant to the Sales Agreement, dated September 5, 2025, entered into by and between the Company and HC Wainwright & Co., LLC. The updated opinion is attached hereto as Exhibit 5.1.

The updated legal opinion does not affect the terms of the ATM Program but provides confirmation regarding the validity of the shares that may be sold under the program and certain matters related to the offering of shares under applicable law.

The foregoing description of the opinion does not purport to be complete and is qualified in its entirety by reference to the full text of the opinion filed as Exhibit 5.1 hereto.

Item 9.01 Financial Statements and Exhibits

(a) Exhibits

Number		Description
5.1		Opinion of Sichenzia Ross Ference Carmel LLP
23.1		Consent of Sichenzia Ross Ference Carmel LLP (included in the opinion filed as Exhibit 5.1)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.

Date: March 12, 2026	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

Source: View Original Filing on SEC EDGAR

FAQ

What did 60 Degrees Pharmaceuticals (SXTP) disclose in this Form 8-K?

60 Degrees Pharmaceuticals reported that it filed an updated legal opinion from its counsel covering shares issued and sold under its at-the-market equity offering program, confirming the validity of those shares and addressing related legal matters without changing the program’s terms.

Does the updated legal opinion change SXTP’s at-the-market equity program?

The updated legal opinion does not change the terms of 60 Degrees Pharmaceuticals’ at-the-market equity offering program. It simply provides legal confirmation about the validity of shares sold under the program and addresses certain matters under applicable securities laws.

Who is SXTP’s sales agent for the at-the-market equity program?

HC Wainwright & Co., LLC is the sales agent for 60 Degrees Pharmaceuticals’ at-the-market equity offering program, under a Sales Agreement dated September 5, 2025, referenced in the filing describing the updated legal opinion of counsel for the program’s shares.

Which law firm provided the updated opinion for 60 Degrees Pharmaceuticals?

Sichenzia Ross Ference Carmel LLP provided the updated legal opinion for 60 Degrees Pharmaceuticals. The opinion is filed as Exhibit 5.1, with its related consent included as Exhibit 23.1, confirming the legality of shares issued and sold under the company’s at-the-market program.

What exhibits did SXTP include with this 8-K filing?

The filing includes Exhibit 5.1, an updated opinion of Sichenzia Ross Ference Carmel LLP, Exhibit 23.1, the firm’s consent included within that opinion, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document, as required for reporting purposes.

Why did 60 Degrees Pharmaceuticals update its legal opinion for ATM shares?

60 Degrees Pharmaceuticals updated its legal opinion to confirm the validity of shares that may be sold under its at-the-market equity offering program and to address related legal matters under applicable law, without altering any existing commercial terms of the sales agreement.

Filing Exhibits & Attachments

5 documents